Single B Cell Based Technology for Monoclonal Antibody Discovery
Yan Lou PhD, Chief Executive Officer, Yurogen Biosystems LLC and SVP at Abclonal, Inc.
Single B cell technology has become an important tool for antibody discovery, particularly for the development of therapeutic antibodies. Single B cells can be isolated from patient blood samples or from immunized animals using various techniques. Once isolated, the DNA or RNA from individual B cells can be amplified and cloned into an expression vector for further screening and identification. Yurogen Biosystems, a subsidiary of ABclonal, has developed a single B cell-based platform (SMab™) for monoclonal antibody discovery from multiple species since 2015. By using the SMab™ platform, Yurogen enables the rapid discovery of high-quality monoclonal antibodies for multiple applications.
Dr. Yang Lou has great expertise in antibody discovery, engineering, and expression. Dr. Yang Lou was the co-founder of Yurogen Biosystems, and the inventor of SMabTM platform. Dr. Lou has received his Ph.D. degree at University of Science and Technology of China and finished his postdoctoral training in UMass Medical School. Over the years, Dr. Lou has gained deep understanding with the market of life science products, as well as strong leadership and managerial skills in biotech industry.
